For research use only. Not for therapeutic Use.
Paquinimod（Cat No.:I008417）, is a chemical compound with promising pharmaceutical potential. This synthetic compound has garnered attention in the field of drug development due to its immunomodulatory properties. It primarily targets the immune system, potentially offering therapeutic benefits in autoimmune disorders and inflammatory conditions. Paquinimod is under investigation for its efficacy in treating diseases like systemic sclerosis and multiple sclerosis. Its CAS number is instrumental in tracking and cataloging the compound for research, development, and regulatory purposes, facilitating its progression through clinical trials and potential future medical applications.
| Catalog Number | I008417 |
| CAS Number | 248282-01-1 |
| Synonyms | ABR‑215757; ABR 215757; ABR215757; Paquinimod.;N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide |
| Molecular Formula | C21H22N2O3 |
| Purity | ≥95% |
| Target | SARS-CoV |
| Solubility | Soluble in DMSO, not in water |
| Storage | 2-8°C |
| IUPAC Name | N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide |
| InChI | InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3 |
| InChIKey | DIKSYHCCYVYKRO-UHFFFAOYSA-N |
| SMILES | CCC1=C2C(=CC=C1)N(C(=O)C(=C2O)C(=O)N(CC)C3=CC=CC=C3)C |
| Reference | </br>1:Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. Stenström M, Nyhlén HC, Törngren M, Liberg D, Sparre B, Tuvesson H, Eriksson H, Leanderson T.J Dermatol Sci. 2016 Jul;83(1):52-9. doi: 10.1016/j.jdermsci.2016.04.006. Epub 2016 Apr 19. PMID: 27156795 Free Article</br>2:Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Schelbergen RF, Geven EJ, van den Bosch MH, Eriksson H, Leanderson T, Vogl T, Roth J, van de Loo FA, Koenders MI, van der Kraan PM, van den Berg WB, Blom AB, van Lent PL.Ann Rheum Dis. 2015 Dec;74(12):2254-8. doi: 10.1136/annrheumdis-2014-206517. Epub 2015 May 12. PMID: 25969431 </br>3:The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte- and context-specific effects. Deronic A, Helmersson S, Leanderson T, Ivars F.Int Immunopharmacol. 2014 Feb;18(2):290-7. doi: 10.1016/j.intimp.2013.12.008. Epub 2013 Dec 23. PMID: 24370393 </br>4:Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells. Helmersson S, Sundstedt A, Deronic A, Leanderson T, Ivars F.Am J Pathol. 2013 May;182(5):1671-80. doi: 10.1016/j.ajpath.2013.01.032. Epub 2013 Mar 16. PMID: 23506849 </br>5:Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, Sparre B, Tuvesson H, Ohman MW, Leanderson T.Arthritis Rheum. 2012 May;64(5):1579-88. doi: 10.1002/art.33493. PMID: 22131101 Free Article |
